SOUTH SAN FRANCISCO (dpa-AFX) - Hoffmann-La Roche announced that on June
27, 2024, Health Canada granted approval of Alecensaro monotherapy as adjuvant
treatment following tumour resection for patients with stage IB to IIIA
anaplastic lymphoma kinase-positive non-small cell lung cancer. The company
noted that Alecensaro is the first and only ALK inhibitor approved for people
with ALK-positive early-stage NSCLC who have undergone surgery to remove their
tumour.

The company said Alecensaro reduced the risk of disease recurrence or death by
76% in people with ALK-positive resected non-small cell lung cancer, as
demonstrated in the Phase III ALINA study.

For More Such Health News, visit rttnews.com.



Copyright(c) 2024 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX